About US
Contact us
-
Progress made in developing first Chlamydia vaccineResearchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually2019/8/14
-
Jazz Pharmaceuticals acquires Cavion in $312.5m dealIrish biopharmaceutical company Jazz Pharmaceuticals has acquired US-based biotechnology firm Cavion for a total potential sum of $312.5m. The deal, which makes Cavion a wholly-owned subsidiary of Ja2019/8/13
-
US Senator seeks records linked to Novartis’ Zolgensma data issuesThe US Senate Finance Committee Chairman Chuck Grassley has asked Novartis to provide information on data manipulation issues related to the company’s subsidiary AveXis’ spinal muscular atrophy (SMA)2019/8/13
-
Sonnet BioTherapeutics agrees to buy Relief TherapeuticsBiotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding. Under the t2019/8/12
-
Explanation found for high mortality in breast cancer patients taking aspirinResearchers from the University of North Carolina (UNC) at Chapel Hill, US, have identified that wide variations in the mortality risk of breast cancer patients taking aspirin could be related to2019/8/12
-
US court rules in favour of Amgen in Enbrel patent caseThe US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine. Amgen companie2019/8/9
-
China approves Gilead’s HIV-1 drug candidate BiktarvyThe China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1 infection. Biktarvy combines the integrase st2019/8/9
-
Canada announces changes to lower medicine pricesThe Government of Canada has made changes to its Patented Medicines Regulations, initially introduced in 1987, in a bid to lower prices of prescription medicines. These reforms are intended to cut do2019/8/8
-
AstraZeneca demonstrates Tagrisso’s superiority to other EGFR-TKI drugsAstraZeneca has published results from its Phase III FLAURA trial showing that in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) its drug Tagriss2019/8/8
-
Oric closes funding to develop glucocorticoid antagonist ORIC-101Oric Pharmaceuticals has closed a Series D financing to support the continued development of a clinical-stage, selective and potent glucocorticoid receptor antagonist, ORIC-101. The company is curren2019/8/7